Toggle navigation
Home
Search
Services
Blog
Contact
About
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I.
Oscient Pharmaceuticals Corporation, Waltham, MA, United States
Search 27 grants from Jen-I Mao
Search grants from Oscient Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Investigating New Roles for Orphan GPCRs in Opioid Actions
Sympathetic Nervous System and Nitric Oxide in Obesity Associated Hypertension
Enhancing Mexican Capacity for CVD Policy Research
Hdl Mediated Cholesterol Clearance From Foam Cells
Pulmonary Complications of Htlv-II/Lav-HIV Infection
Recently added grants:
Smarter exosomes derived from engineered MSCs promote neo-vascularization
R01- Mapping environmental contributions to rapid lung disease progression in cystic fibrosis
Effects of Rare Variants and Ancestry on Beta Agonist Response in Asthma and COPD
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV
Data and Research Support Center
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HG000295-03
Application #
2208690
Study Section
Special Emphasis Panel (ZRG7-SSS-2 (08))
Project Start
1991-02-01
Project End
1996-11-30
Budget Start
1994-12-01
Budget End
1996-11-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Oscient Pharmaceuticals Corporation
Department
Type
DUNS #
City
Waltham
State
MA
Country
United States
Zip Code
02453
Related projects
NIH 1995
R44 HG
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I. / Oscient Pharmaceuticals Corporation
NIH 1994
R44 HG
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I. / Oscient Pharmaceuticals Corporation
Comments
Be the first to comment on this grant